MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.

To report the clinical findings and long-term results of front-line, third-generation MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin) chemotherapy and mediastinal involved-field radiotherapy (IFRT) in 85 consecutive, previously untreated patients with primary mediastinal large B cell lymphoma (PMLBCL) diagnosed and managed at a single institution.
Between 1991 and April 2004, 92 consecutive, untreated patients with PMLBCL were treated at our institution. The median age was 33 years (range, 15-61 years), 46 patients (50%) showed a mediastinal syndrome at onset; 52 patients (57%) showed a low/low-intermediate (0 to 1) and 40 patients (43%) an intermediate-high/high (2 to 3) International Prognostic Index (IPI) score. Eighty-five patients were treated with standard chemotherapy (MACOP-B), and 80 underwent mediastinal IFRT at a dose of 30-36 Gy.
After a MACOP-B regimen, the overall response rate was 87% and the partial response rate 9%. After chemotherapy, (67)Ga scintigraphy/positron emission tomography results were positive in 43 of 52 patients (83%), whereas after IFRT 11 of 52 patients (21%) remained positive (p < 0.0001). After a median follow-up of 81 months (range, 2-196 months), progression or relapse was observed in 15 of 84 patients (18%). The projected 5-year overall survival and progression-free survival rates were 87% and 81%, respectively. The 5-year overall survival and progression-free survival rates were better for patients with an IPI of 0 to 1 than for those with an IPI of 2 to 3 (96% vs. 73% [p = 0.002] and 90% vs. 67% [p = 0.007], respectively).
Combined-modality treatment with intensive chemotherapy plus mediastinal IFRT induces high response and lymphoma-free survival rates. Involved-field RT plays an important role in inducing negative results on (67)Ga scintigraphy/positron emission tomography in patients responsive to chemotherapy.
AuthorsVitaliana De Sanctis, Erica Finolezzi, Mattia Falchetto Osti, Lavinia Grapulin, Marco Alfò, Edoardo Pescarmona, Francesca Berardi, Fiammetta Natalino, Maria Luisa Moleti, Alice Di Rocco, Riccardo Maurizi Enrici, Robin Foà, Maurizio Martelli
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 72 Issue 4 Pg. 1154-60 (Nov 15 2008) ISSN: 1879-355X [Electronic] United States
PMID18472357 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Bleomycin
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Leucovorin
  • Prednisone
  • Methotrexate
  • Adolescent
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
  • Bleomycin (administration & dosage)
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Humans
  • Italy (epidemiology)
  • Leucovorin (administration & dosage)
  • Longitudinal Studies
  • Lymphoma, B-Cell (mortality, therapy)
  • Mediastinal Neoplasms (mortality, therapy)
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Prednisone (administration & dosage)
  • Prevalence
  • Radiotherapy, Adjuvant
  • Survival Analysis
  • Survival Rate
  • Treatment Outcome
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: